1 / 20

Dementia

Dementia. Caroline Harada, M.D. Associate Professor of Medicine UAB Division of Gerontology, Geriatrics, and Palliative Care November 2013. Dementia Defined. Decline in cognitive function from baseline. Epidemiology. Dementia in the US population Over 65: 5-10% Over 85: 30-50%.

ovid
Download Presentation

Dementia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dementia Caroline Harada, M.D. Associate Professor of Medicine UAB Division of Gerontology, Geriatrics, and Palliative Care November 2013

  2. Dementia Defined Decline in cognitive function from baseline

  3. Epidemiology Dementia in the US population • Over 65: 5-10% • Over 85: 30-50% Kennedy, GJ. Geriatric Medicine, 4th Ed. Cassel et al, Eds. 2003. p.1079; Gauthier S et al. Lancet 2006. 376: 1262-1270.

  4. DSM-5: Major Neurocognitive Disorder Decline from prior level of performance in at least 1 cognitive domain: 1. Complex attention 2. Executive function 3. Learning and memory 4. Language 5. Perceptual-motor 6. Social cognition Based on history and quantified clinical assessment Interfering with independence in everyday activities Not exclusively with delirium, psychiatric disorders Diagnostic and Statistical Manual of Mental Disorders, 5th Ed, 2013

  5. Dementia types 5% Other 5-10% DLB 5-10% Vascular 15-20% Mixed 60% Alzheimer Disease

  6. Alzheimer Disease • New diagnostic criteria published in 2011 • Clinical criteria • Insidious onset of months to years • Progression of cognitive decline • Amnestic or nonamnestic symptoms • Differential diagnosis of Alzheimer dementia • Biomarkers • Accumulation of amyloid beta • Neuronal injury

  7. Vascular Dementia Due to large or small vessel disease Stepwise progression of symptoms Executive function and processing speed can decline first, followed by memory, language, etc.

  8. Dementia with Lewy Bodies • Characteristics • Prominent visual hallucinations • Parkinsonism (gait, balance, rigidity, bradykinesia- rest tremor less common) • Falls or gait difficulties • Fluctuations in cognition • Sensitivity to antipsychotics (extrapyramidal side effects) • Also • REM sleep behavior disorder • Decreased sympathetic function Knopman DS. Mayo ClinProc, 2006; Blass DM, Rabins PV. Annals Int Med, 2008

  9. Clinical Evaluation • History • Physical Examination • Vascular disease • Neurological exam • Laboratories • B12, TSH, RPR, HIV, Vit D • Imaging • Brain CT or MRI • Neuropsychological testing

  10. Dementia Drugs

  11. Dementia Drugs Card Sort

  12. Acetylcholinesterase Inhibitors • Donepezil (Aricept) • Galantamine (Razadyne) • Rivastigmine (Exelon)

  13. Efficacy Rogers: Neurology, 1998.136-145

  14. Trinh NH et al. JAMA. 2003 Jan 8;289(2):210-6.

  15. Efficacy: Cholinesterase Inhibitors Statistically significant? Yes. Clinically significant? Maybe? Adverse effects: nausea, vomiting, diarrhea, dizziness, tremor, and bradycardia Raina, P et al. Ann Intern Med. 2008

  16. NMDA antagonist: Memantine(Namenda) • Mechanism of action: inhibition of glutamate • Randomized, placebo-controlled trials show similarly small (but statistically significant) benefits Reisberg B et al. NEJM 2003; Raina, P et al. Ann Intern Med. 2008

  17. NMDA antagonist Memantine (Namenda) Reisberg B et al. NEJM 2003

  18. FDA-approved only for moderate to severe dementia Adverse effects: minimal Benefit to combination therapy with cholinesterase inhibitors: unclear Howard R et al, N Engl J Med. 2012 Mar 8; 366(10):893-903

  19. Drug candidates that to date have no proven efficacy Anti-inflammatories Statins Estrogen Antioxidants Gingko biloba Fish oil, omega-3 fatty acids Vitamin E Lowering homocysteine Alcohol, especially wine Huperzine Curcumin Nicotine Insulin & insulin sensitizers, ketones

  20. Dementia andEnd of Life Issues

More Related